RAPT - RAPT Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
422.32M
Enterprise Value 3
132.86M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-3.37

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3∞%
S&P500 52-Week Change 313.08%
52 Week High 342.00
52 Week Low 311.85
50-Day Moving Average 318.25
200-Day Moving Average 318.25

Share Statistics

Avg Vol (3 month) 3135.36k
Avg Vol (10 day) 3149.1k
Shares Outstanding 521.28M
Float 258.69k
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short (Oct 31, 2019) 4N/A
Short Ratio (Oct 31, 2019) 40
Short % of Float (Oct 31, 2019) 40.00%
Short % of Shares Outstanding (Oct 31, 2019) 40.00%
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -39.45M
Net Income Avi to Common (ttm)-39.53M
Diluted EPS (ttm)-58.21
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)59.86M
Total Cash Per Share (mrq)73.65
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)10.53
Book Value Per Share (mrq)-142.11

Cash Flow Statement

Operating Cash Flow (ttm)-35.72M
Levered Free Cash Flow (ttm)N/A